FDA expands a bladder cancer drug to patients whose papillary tumors resist standard treatment
The approval of Anktiva with BCG rests on evidence from an earlier approval in a related form of the disease.
The approval of Anktiva with BCG rests on evidence from an earlier approval in a related form of the disease.